SCHEMBL5773090

SCHEMBL5773090

Cc1ccc(CC(=O)O)cc1S(=O)(=O)N1CCN(c2ccc(C(C)(C)C)cc2)CC1

nearest known ligand 0.53

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
HSD11B1 P28845 6/20 0.53
SMN1; SMN2 Q16637 2/20 0.47
LMNA P02545 1/20 0.47
REV1 Q9UBZ9 1/20 0.46
TNF P01375 1/20 0.45
RAB9A P51151 1/20 0.45
NOD1 Q9Y239 1/20 0.45
POLB P06746 2/20 0.45
MAPT P10636 2/20 0.45
NR1H4 Q96RI1 1/20 0.45
THRB P10828 1/20 0.45
MEN1 O00255 1/20 0.43
KMT2A Q03164 1/20 0.43
BCL2 P10415 1/20 0.42
BCL2L1 Q07817 1/20 0.42
MCL1 Q07820 1/20 0.42
BCL2A1 Q16548 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5746517 0.88 L3MBTL1 (0.52) HSD11B1SMN1; SMN2LMNAREV1TNF
SCHEMBL6349294 0.88 MAPT (0.52) SMN1; SMN2LMNAREV1TNFRAB9A
SCHEMBL5747352 0.86 MAPK1 (0.55) HSD11B1SMN1; SMN2LMNAPOLBMAPT
SCHEMBL6351806 0.85 TNF (0.48) SMN1; SMN2LMNAREV1TNFRAB9A
SCHEMBL5798425 0.85 THRB (0.56) SMN1; SMN2LMNAREV1MAPTTHRB
SCHEMBL6348350 0.83 HSD11B1 (0.59) HSD11B1SMN1; SMN2LMNAMAPTTHRB
SCHEMBL6348660 0.82 LMNA (0.48) LMNAMAPT
SCHEMBL6349175 0.82 HSD11B1 (0.61) HSD11B1POLBMAPTMEN1KMT2A
SCHEMBL5775668 0.80 MAPT (0.53) SMN1; SMN2LMNARAB9APOLBMAPT
SCHEMBL5749721 0.79 MAPT (0.53) SMN1; SMN2LMNARAB9APOLBMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1735280-A1 ARYL SULFONAMIDE AND SULFONYL COMPOUNDS AS MODULATORS OF PPAR AND METHODS OF TREATING METABOLIC DISORDERS Kalypsys, Inc. (US) 2006-12-27 EP disclosed
WO-2005115983-A1 ARYL SULFONAMIDE AND SULFONYL COMPOUNDS AS MODULATORS OF PPAR AND METHODS OF TREATING METABOLIC DISORDERS KALYPSYS, INC. (US) 2005-12-08 WO disclosed
US-20050234046-A1 Aryl sulfonamide and sulfonyl compounds as modulators of PPAR and methods of treating metabolic disorders KALYPSYS, INC. (US) 2005-10-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050234046-A1 Aryl sulfonamide and sulfonyl compounds as modulators of PPAR and methods of treating metabolic disorders PPARA, PPARG, PPARD HSD11B1 668/4885SMN1; SMN2 2173/4885LMNA 3289/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.